Table 3.
The results of performed meta-analysis in subgroups of product and tumor.
| Subgroup | ORR, (95% CI) | CRR, (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|
| tisa-cel | axi-cel | liso-cel | Overall | tisa-cel | axi-cel | liso-cel | Overall | |
| All patients | 69% (.58–.79) | 77% (.71–.82) | 73% (.67–.78) | 73% (.68–.77) | 57% (.41–.72) | 52% (.46–.58) | 53% (.47–.59) | 54% (.48–.59) |
| DLBCL | 53% (.44–.61) | 75% (.67–.83) | 72% (.65–.78) | 70% (.63–.76) | 40% (.32–.49) | 52% (.44–.60) | 52% (.45–.59) | 50% (.45–.56) |
| FL/tFL | 86% (.64–1.00) | 81% (.69–.90) | NA | 83% (.73–.92) | 73% (.48–.93) | 64% (.54–.74) | NA | 66% (.56–.76) |
| ALL | 81% (.69–.90) | NA | NA | 81% (.69–.90) | 81% (.69–.90) | NA | NA | 81% (.69–.90) |
| Subgroup | CRS, (95% CI) | ICANS, (95% CI) | ||||||
| tisa-cel | axi-cel | liso-cel | Overall | tisa-cel | axi-cel | liso-cel | Overall | |
| All patients | 21% (.07–.38) | 9% (.07–.12) | 2% (.01–.05) | 13% (.09–.19) | 8% (.05–.12) | 31% (.27–.35) | 10% (.07–.14) | 22% (.17–.27) |
| DLBCL | 8% (.01–.21) | 8% (.05–.12) | NA | 9% (.07–.13) | 8% (.03–.13) | 32% (.26–.38) | NA | 25% (.19–.31) |
| FL/tFL | NA | 2% (.00–.08) | NA | 2% (.00–.08) | NA | 31% (.18–.46) | NA | 31% (.18–.46) |
| ALL | 55% (.45–.64) | NA | NA | 55% (.45–.64) | 11% (.05–.17) | NA | NA | 11% (.05–.17) |
ORR, overall response rate; CRR, complete response rate; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; DLBCL, diffuse large B cell lymphoma; FL/tFL, follicular lymphoma or transformed follicular lymphoma; ALL, acute lymphoblastic leukemia; NA, not applicable.